Abstract
Perampanel (PER) has gained a current approval for monotherapy of treating focal-onset seizures with or without secondarily generalized seizures, and as an adjuvant therapy with concomitant antiepileptic drug (AED) for primary generalized seizures in patients aged older than 4 years. The recent studies on its monotherapy have become a breakthrough by recognizing its vast potential in clinical practices. This systematic review is aimed to correlate all the studies on monotherapy to validate the efficacy and safety profile of the drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
